Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Reactive myelopoiesis and FX-expressing macrophages triggered by chemotherapy promote cancer lung metastasis
Caijun Wu, Qian Zhong, Rejeena Shrestha, Jingzhi Wang, Xiaoling Hu, Hong Li, Eric C. Rouchka, Jun Yan, Chuanlin Ding
Caijun Wu, Qian Zhong, Rejeena Shrestha, Jingzhi Wang, Xiaoling Hu, Hong Li, Eric C. Rouchka, Jun Yan, Chuanlin Ding
View: Text | PDF
Research Article Immunology

Reactive myelopoiesis and FX-expressing macrophages triggered by chemotherapy promote cancer lung metastasis

  • Text
  • PDF
Abstract

Several preclinical studies have demonstrated that certain cytotoxic drugs enhance metastasis, but the importance of host responses triggered by chemotherapy in regulating cancer metastasis has not been fully explored. Here, we showed that multidose gemcitabine (GEM) treatment promoted breast cancer lung metastasis in a transgenic spontaneous breast cancer model. GEM treatment significantly increased accumulation of CCR2+ macrophages and monocytes in the lungs of tumor-bearing as well as tumor-free mice. These changes were largely caused by chemotherapy-induced reactive myelopoiesis biased toward monocyte development. Mechanistically, enhanced production of mitochondrial ROS was observed in GEM-treated BM Lin−Sca1+c-Kit+ cells and monocytes. Treatment with the mitochondria targeted antioxidant abrogated GEM-induced hyperdifferentiation of BM progenitors. In addition, GEM treatment induced upregulation of host cell–derived CCL2, and knockout of CCR2 signaling abrogated the pro-metastatic host response induced by chemotherapy. Furthermore, chemotherapy treatment resulted in the upregulation of coagulation factor X (FX) in lung interstitial macrophages. Targeting activated FX (FXa) using FXa inhibitor or F10 gene knockdown reduced the pro-metastatic effect of chemotherapy. Together, these studies suggest a potentially novel mechanism for chemotherapy-induced metastasis via the host response–induced accumulation of monocytes/macrophages and interplay between coagulation and inflammation in the lungs.

Authors

Caijun Wu, Qian Zhong, Rejeena Shrestha, Jingzhi Wang, Xiaoling Hu, Hong Li, Eric C. Rouchka, Jun Yan, Chuanlin Ding

×

Figure 6

GEM-induced pro-metastatic host response is dependent on CCL2/CCR2-mediated recruitment of monocytes.

Options: View larger image (or click on image) Download as PowerPoint
GEM-induced pro-metastatic host response is dependent on CCL2/CCR2-media...
(A) Mouse cytokine/chemokine array of pooled plasma from the PBS- or GEM-treated mice. (B) qRT-PCR for CCL2 gene in lung tissues from GEM- and PBS-treated mice (n = 7–10). (C) Lung macrophages were sorted from naive mice and stimulated with recombinant mouse FXa (Haematologic Technologies, 1 U/mL) for 24 hours. The mouse cytokine/chemokine profile in the culture supernatant was examined using cytokine/chemokine array. (D) Mean fluorescence intensity of CCR2 expression on lung monocytes and macrophages (n = 5). (E) B6 WT and CCR2-KO mice were treated with 4 doses of GEM followed by intravenous injection of 4 × 105 E0771-GFP cells. The percentage of GFP+ tumor cells within CD45– cell population was summarized (n = 5). (F) Experimental scheme for adoptive transfer of BM monocytes (1.5 × 106/mouse) from PBS- and GEM-treated mice and E0771-GFP (4 × 105/mouse) injection. (G) The lung tumor burden was examined by measuring GFP+ tumor cells within lung CD45– cells 14 days after tumor cell injection (n = 7–8). *P < 0.05 and **P < 0.01 by unpaired 2-sided t test (B, D, and G) or ordinary 1-way ANOVA (E).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts